The nemesis comes from China. The full name of Beijing Kexing Biological Products Co., Ltd. is the first vaccine enterprise listed in the United States in China. Beijing Branch has established a professional R&D and management system, and formed a research and development mode with enterprises as the main body and Industry-University-Research as the combination. We have successful experience and technical team in the research and development of new vaccines, insist on independent innovation to build core competitiveness, adopt advanced technology to continuously develop new vaccines and carry out technical transformation on traditional vaccines.

Beijing Kexing Biological Products Co., Ltd.:

The purpose of the company's establishment and operation: in line with the desire to develop China's bioengineering high-tech industry, we will adopt advanced scientific and technological achievements at home and abroad and introduce international scientific management methods to conduct research, production and sales of human vaccines and related products, and provide technical consultation and technical services to improve the prevention and treatment level of various major diseases at home and abroad, including hepatitis A and hepatitis B, and make contributions to human health.